Meant to B: B cells as a therapeutic target in systemic lupus erythematosus

B cells have a prominent role in the pathogenesis of systemic lupus erythematosus (SLE). They are mediators of inflammation through the production of pathogenic antibodies that augment inflammation and cause direct tissue and cell damage. Multiple therapeutic agents targeting B cells have been successfully used in mouse models of SLE; however, these preclinical studies have led to approval of only one new agent to treat patients with SLE: belimumab, a monoclonal antibody targeting B cell-activating factor (BAFF). Integrating the experience acquired from previous clinical trials with the knowledge generated by new studies about mechanisms of B cell contributions to SLE in specific groups of patients is critical to the development of new treatment strategies that will help to improve outcomes in patients with SLE. In particular, a sharper focus on B cell differentiation to plasma cells is warranted.

Automated summary

B cells play a key role in the development of SLE, producing pathogenic antibodies that enhance inflammation and damage tissues and cells. While multiple therapies targeting B cells have been successful in mouse models, only belimumab has been approved for SLE treatment in patients. Integrating previous clinical trial experience with new research on B cell mechanisms in specific patient groups is crucial for developing effective treatment strategies, particularly focusing on B cell differentiation into plasma cells.